BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 25829083)

  • 1. 18F FDG PET/CT and Head and Neck Cancer: Patient Management and Outcomes.
    Sheikhbahaei S; Marcus C; Subramaniam RM
    PET Clin; 2015 Apr; 10(2):125-45. PubMed ID: 25829083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 18F fluorodeoxyglucose PET/CT in head and neck squamous cell carcinoma with negative neck palpation findings: a prospective study.
    Roh JL; Park JP; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    Radiology; 2014 Apr; 271(1):153-61. PubMed ID: 24475791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Present and future role of FDG-PET/CT imaging in the management of head and neck carcinoma.
    Kitajima K; Suenaga Y; Sugimura K
    Jpn J Radiol; 2015 Dec; 33(12):776-89. PubMed ID: 26507982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on 18F-fluorodeoxyglucose/positron emission tomography and positron emission tomography/computed tomography imaging of squamous head and neck cancers.
    Menda Y; Graham MM
    Semin Nucl Med; 2005 Oct; 35(4):214-9. PubMed ID: 16150243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of pretreatment 18F-FDG PET/CT parameters including visual evaluation in patients with head and neck squamous cell carcinoma.
    Koyasu S; Nakamoto Y; Kikuchi M; Suzuki K; Hayashida K; Itoh K; Togashi K
    AJR Am J Roentgenol; 2014 Apr; 202(4):851-8. PubMed ID: 24660716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics and Limitations of FDG PET/CT for Imaging of Squamous Cell Carcinoma of the Head and Neck: A Comprehensive Review of Anatomy, Metastatic Pathways, and Image Findings.
    Plaxton NA; Brandon DC; Corey AS; Harrison CE; Karagulle Kendi AT; Halkar RK; Barron BJ
    AJR Am J Roentgenol; 2015 Nov; 205(5):W519-31. PubMed ID: 26496574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of five segmentation tools for 18F-fluoro-deoxy-glucose-positron emission tomography-based target volume definition in head and neck cancer.
    Schinagl DA; Vogel WV; Hoffmann AL; van Dalen JA; Oyen WJ; Kaanders JH
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1282-9. PubMed ID: 17967318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary assessment of dynamic contrast-enhanced CT implementation in pretreatment FDG-PET/CT for outcome prediction in head and neck tumors.
    Abramyuk A; Wolf G; Shakirin G; Haberland U; Tokalov S; Koch A; Appold S; Zöphel K; Abolmaali N
    Acta Radiol; 2010 Sep; 51(7):793-9. PubMed ID: 20583948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of FDG-PET/CT on the management of head and neck tumours: the radiotherapist's perspective.
    Dietl B; Marienhagen J; Kühnel T; Schreyer A; Kölbl O
    Oral Oncol; 2008 May; 44(5):504-8. PubMed ID: 17826307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment.
    Yao M; Smith RB; Graham MM; Hoffman HT; Tan H; Funk GF; Graham SM; Chang K; Dornfeld KJ; Menda Y; Buatti JM
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):991-9. PubMed ID: 16099601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. (18)F-Fluorodeoxyglucose PET/MR Imaging in Head and Neck Cancer.
    Platzek I
    PET Clin; 2016 Oct; 11(4):375-86. PubMed ID: 27593244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers.
    Andrade RS; Heron DE; Degirmenci B; Filho PA; Branstetter BF; Seethala RR; Ferris RL; Avril N
    Int J Radiat Oncol Biol Phys; 2006 Aug; 65(5):1315-22. PubMed ID: 16750327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of intrathoracic lesions detected by 18F-fluorodeoxyglucose positron emission tomography in the management of patients with head and neck cancer.
    Roh JL; Ryu CH; Kim JS; Lee JS; Choi SH; Nam SY; Kim SY
    Oral Oncol; 2007 Sep; 43(8):757-63. PubMed ID: 17112773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of 18F-FDG PET/CT as a predictive biomarker of outcome in patients with head-and-neck non-squamous cell carcinoma.
    Imsande HM; Davison JM; Truong MT; Devaiah AK; Mercier GA; Ozonoff AJ; Subramaniam RM
    AJR Am J Roentgenol; 2011 Oct; 197(4):976-80. PubMed ID: 21940588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potential role of non-FDG-PET in the management of head and neck cancer.
    Heuveling DA; de Bree R; van Dongen GA
    Oral Oncol; 2011 Jan; 47(1):2-7. PubMed ID: 21109481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer.
    Moeller BJ; Rana V; Cannon BA; Williams MD; Sturgis EM; Ginsberg LE; Macapinlac HA; Lee JJ; Ang KK; Chao KS; Chronowski GM; Frank SJ; Morrison WH; Rosenthal DI; Weber RS; Garden AS; Lippman SM; Schwartz DL
    J Clin Oncol; 2009 May; 27(15):2509-15. PubMed ID: 19332725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-fluoro-deoxy-glucose-positron emission tomography/computed tomography in diagnosis of head and neck squamous cell carcinoma: a systematic review and meta-analysis.
    Rohde M; Dyrvig AK; Johansen J; Sørensen JA; Gerke O; Nielsen AL; Høilund-Carlsen PF; Godballe C
    Eur J Cancer; 2014 Sep; 50(13):2271-9. PubMed ID: 25011659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential for truncating the scan length of restaging FDG-PET/CT after chemoradiotherapy in head and neck squamous cell carcinoma.
    Huang YT; Ravi Kumar AS
    Nucl Med Commun; 2012 May; 33(5):503-8. PubMed ID: 22262244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of FDG-PET/CT imaging on nodal staging for head-and-neck squamous cell carcinoma.
    Murakami R; Uozumi H; Hirai T; Nishimura R; Shiraishi S; Ota K; Murakami D; Tomiguchi S; Oya N; Katsuragawa S; Yamashita Y
    Int J Radiat Oncol Biol Phys; 2007 Jun; 68(2):377-82. PubMed ID: 17321066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
    Schaefferkoetter JD; Carlson ER; Heidel RE
    J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.